Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 7/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918368 | 0.87 | SNCA (0.65) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| SCHEMBL8374037 | 0.85 | CYP1A2 (0.53) | SNCACYP1A2ALDH1A1CYP2C19TSHR | |
| SCHEMBL7874618 | 0.85 | SNCA (0.59) | SNCAHIF1ACYP1A2ALDH1A1CYP2C19 | |
| Bromide SCHEMBL163158 | 0.84 | SNCA (0.67) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| Fluoride Ion SCHEMBL585089 | 0.84 | SNCA (0.63) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL494 | 0.84 | SNCA (0.63) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| Water SCHEMBL3422802 | 0.84 | SNCA (0.63) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| Iodide SCHEMBL159922 | 0.84 | SNCA (0.63) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| SCHEMBL989761 | 0.84 | SNCA (0.63) | SNCACPA1HIF1ACYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5427779 | 0.83 | CYP1A2 (0.51) | SNCACYP1A2ALDH1A1CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356150-A1 | BIOBASED DIISOCYANATES, AND PROCESS FOR PREPARATION OF SAME | Evoco Limited (CA) | 2022-11-10 | — | — | US | disclosed |
| EP-4083018-A1 | BIOBASED DIISOCYANATES, AND PROCESS FOR PREPARATION OF SAME | Evoco Limited (CA) | 2022-11-02 | — | — | EP | disclosed |
| CN-115260448-A | Bio-based diisocyanate, preparation method thereof and polyurethane elastomer | Evoco有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11358929-B1 | Biobased diisocyanates, and process for preparation of same | EVOCO LTD (CA) | 2022-06-14 | — | — | US | disclosed |
| US-11214539-B1 | Biobased diisocyanates, and process for preparation of same | Evoco Limited (CA) | 2022-01-04 | — | — | US | disclosed |
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356150-A1 | BIOBASED DIISOCYANATES, AND PROCESS FOR PREPARATION OF SAME | CES2, CNPY3, NCEH1 | SNCA 3450/4885CPA1 764/4885HIF1A 4546/4885 |
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | SNCA 3385/4885CPA1 2578/4885HIF1A 570/4885 |
| US-11214539-B1 | Biobased diisocyanates, and process for preparation of same | ROS1, CROCC, RCN1 | SNCA 863/4885CPA1 2589/4885HIF1A 1639/4885 |
| US-11358929-B1 | Biobased diisocyanates, and process for preparation of same | CES2, CNPY3, NCEH1 | SNCA 3270/4885CPA1 726/4885HIF1A 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.